Table 3.
Univariate and multivariate Cox proportional hazard analysis for overall survival and progression free survival
| Prognostic Factor | Overall Survival | Progression Free Survival | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Univariate HR (95% CI) | P | Multivariate HR (95% CI) | P | Univariate HR (95% CI) | P | Multivariate HR (95% CI) | P | |
| Gender | ||||||||
| Female | 1 (Referent) | 1 (Referent) | ||||||
| Male | 1.109 (0.785-1.566) | 0.558 | ... | 1.051 (0.770-1.434) | 0.755 | ... | ||
| Age | ||||||||
| < 60 y | 1 (Referent) | 1 (Referent) | 1 (Referent) | |||||
| ≥ 60 y | 1.636 (1.130-2.370) | 0.009 | 1.591 (1.095-2.313) | 0.015 | 1.593 (1.142-2.222) | 0.006 | 1.567 (1.122-2.188) | 0.008 |
| Tumor size | ||||||||
| < 5 cm | 1 (Referent) | 1 (Referent) | ||||||
| ≥ 5 cm | 0.892 (0.626-1.270) | 0.525 | ... | 0.848 (0.614-1.170) | 0.314 | ... | ||
| Tumor site | ||||||||
| Rectum | 1 (Referent) | 1 (Referent) | ||||||
| Right colon | 1.008 (0.641-1.586) | 0.973 | ... | 0.859 (0.564-1.308) | 0.479 | ... | ||
| Left colon | 1.378 (0.940-2.022) | 0.101 | ... | 1.275 (0.904-1.800) | 0.167 | ... | ||
| Pathological type | ||||||||
| Protrude | 1 (Referent) | 1 (Referent) | 1 (Referent) | 1 (Referent) | ||||
| Infiltrative | 3.516 (1.733-7.131) | < 0.001 | 2.704 (1.316-5.557) | 0.007 | 3.077 (1.534-6.172) | 0.002 | 2.661 (1.312-5.395) | 0.007 |
| Ulcerative | 1.747 (1.176-2.595) | 0.006 | 1.617 (1.077-2.427) | 0.020 | 1.956 (1.359-2.815) | < 0.001 | 1.804 (1.246-2.611) | 0.002 |
| Histological type | ||||||||
| Tubular adenocarcinoma | 1 (Referent) | 1 (Referent) | 1 (Referent) | |||||
| Mucinous adenocarcinoma | 0.800 (0.419-1.528) | 0.499 | 0.734 (0.382-1.413) | 0.355 | 0.773 (0.429-1.395) | 0.393 | ... | |
| Others | 2.009 (1.052-3.835) | 0.034 | 2.225 (1.141-4.342) | 0.019 | 1.787 (0.968-3.302) | 0.064 | ... | |
| T stage | ||||||||
| T1/T2 | 1 (Referent) | 1 (Referent) | ||||||
| T3/T4 | 2.387 (1.253-4.549) | 0.008 | ... | 2.251 (1.277-3.968) | 0.005 | ... | ||
| N stage | ||||||||
| N0 | 1 (Referent) | 1 (Referent) | 1 (Referent) | 1 (Referent) | ||||
| N1-2 | 2.584 (1.793-3.723) | < 0.001 | 2.089 (1.432-3.047) | < 0.001 | 2.173 (1.578-2.994) | < 0.001 | 1.822 (1.310-2.532) | < 0.001 |
| M stage | ||||||||
| M0 | 1 (Referent) | 1 (Referent) | 1 (Referent) | 1 (Referent) | ||||
| M1 | 2.565 (1.706-3.857) | < 0.001 | 2.114 (1.394-3.206) | < 0.001 | 2.283 (1.557-3.348) | < 0.001 | 1.905 (1.289-2.817) | 0.001 |
| KRAS Status | ||||||||
| Wild type | 1 (Referent) | 1 (Referent) | 1 (Referent) | 1 (Referent) | ||||
| All codon 12 mutants | 2.495 (1.741-3.575) | < 0.001 | 2.846 (1.967-4.118) | < 0.001 | 1.867 (1.349-2.584) | < 0.001 | 2.011 (1.450-2.789) | < 0.001 |
| All codon 13 mutants | 1.537 (0.839-2.817) | 0.164 | 1.776 (0.961-3.281) | 0.067 | 1.450 (0.857-2.453) | 0.166 | 1.564 (0.921-2.654) | 0.098 |
| CEA | ||||||||
| < 5 ng/ml | 1 (Referent) | 1 (Referent) | ||||||
| ≥ 5 ng/ml | 2.079 (1.452-2.976) | < 0.001 | ... | 1.795 (1.307-2.464) | < 0.001 | ... | ||
| CA19-9 | ||||||||
| < 27 U/ml | 1 (Referent) | 1 (Referent) | ||||||
| ≥ 27 U/ml | 1.341 (0.948-1.896) | 0.097 | ... | 1.247 (0.909-1.710) | 0.171 | ... | ||
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; HR, hazard ratio; 95% CI, 95% confidence interval.